Altimmune, Inc. Contracts & Agreements

Employment Agreement, dated November 6, 2024, by and between Altimmune, Inc. and Greg Weaver (Filed With SEC on November 12, 2024)

Description of Registrants Securities (Filed With SEC on March 27, 2024)

Description of Registrants Securities (Filed With SEC on February 28, 2023)

Altimmune, Inc. Non-Employee Director Compensation Policy (Filed With SEC on February 28, 2023)

Employment Agreement, dated January 1, 2023, by and between Altimmune, Inc. and Raymond M. Jordt (Filed With SEC on February 28, 2023)

Description of Registrants Securities (Filed With SEC on March 15, 2022)

Employment Agreement, dated December 10, 2021, by and between Altimmune, Inc. and Richard I. Eisenstadt (Filed With SEC on December 13, 2021)

Amendment No. 8 Contract Award issued by the Biomedical Advanced Research and Development Authority of the United Sates Department of Health and Human Services, dated September... (Filed With SEC on November 9, 2021)

Amendment No. 7 Contract Award issued by the Biomedical Advanced Research and Development Authority of the United Sates Department of Health and Human Services, dated June 29, 2021 (Filed With SEC on August 10, 2021)

Amendment No. 6 to the Second Restated License Agreement, effective as of January 22, 2021, between Janssen Vaccines & Prevention B.V. (formerly Crucell Holland B.V.) and... (Filed With SEC on May 17, 2021)

Statement of Work, dated March 9, 2021, by and between Altimmune, Inc. and Lonza Houston Inc (Filed With SEC on May 17, 2021)

Description of Registrants Securities (Filed With SEC on February 25, 2021)

Amendment No. 5 to Second Restated License Agreement, effective as of October 22, 2020, between Janssen Vaccines & Prevention B.V. (formerly Crucell Holland B.V.) and Altimmune,... (Filed With SEC on February 25, 2021)

Amendment No. 6 to Contract Award issued by the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services, dated December... (Filed With SEC on February 25, 2021)

Equity Distribution Agreement, dated February 25, 2021, by and among Altimmune, Inc. and Piper Sandler & Co., Evercore Group L.L.C. and B. Riley Securities, Inc (Filed With SEC on February 25, 2021)

Form of Pre-Funded Warrant (Filed With SEC on February 25, 2021)

Exchange Agreement between Altimmune, Inc. and Venrock Healthcare Capital Partners II, L.P., Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings II, LLC and... (Filed With SEC on February 25, 2021)

Amendment No. 4 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of July 28, 2020 (Filed With SEC on November 9, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on November 9, 2020)

Amendment No. 2 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of September 20, 2016 (Filed With SEC on August 11, 2020)

Amendment No. 3 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of April 2, 2020 (Filed With SEC on August 11, 2020)

Underwriting Agreement, dated as of July 13, 2020, among Altimmune, Inc. and Jefferies LLC, Evercore Group L.L.C. and Piper Sandler & Co., as representatives of the underwriters... (Filed With SEC on July 16, 2020)

Form of Pre-Funded Warrant (Filed With SEC on July 16, 2020)

Description of Registrants Securities (Filed With SEC on March 27, 2020)

Equity Distribution Agreement, dated March 27, 2020, by and among Altimmune, Inc. and JMP Securities LLC (Filed With SEC on March 27, 2020)

Amended and Restated License Agreement, dated July 12, 2019, by and between Mederis Diabetes, LLC and Spitfire Pharma, Inc (Filed With SEC on November 13, 2019)

Amendment No. 5 to Contract Award issued by Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services, dated August 20,... (Filed With SEC on November 13, 2019)

Employment Agreement, dated September 3, 2019, by and between the Company and M. Scott Harris, M.D (Filed With SEC on November 13, 2019)

Transition Services Agreement, by and between the Company and Sybil Tasker, M.D., MPH, dated June 17, 2019 (Filed With SEC on August 13, 2019)

Release of Claims Agreement, by and between the Company and Dr. Tasker, dated June 17, 2019 (Filed With SEC on August 13, 2019)

Form of Lock-Up Agreement (Filed With SEC on July 9, 2019)

Agreement and Plan of Merger and Reorganization, dated July 8, 2019, by and among Altimmune, Inc., Springfield Merger Sub, Inc., Springfield Merger Sub, LLC, Spitfire Pharma, Inc.... (Filed With SEC on July 9, 2019)

Employment Agreement, dated June 10, 2019, by and between Altimmune, Inc. and William Brown (Filed With SEC on June 12, 2019)

Amendment, dated March 14, 2019, to Consulting Agreement, dated May 21, 2018, by and between Altimmune Inc., and William Brown (Filed With SEC on March 15, 2019)

Placement Agency Agreement among Altimmune, Inc. and Roth Capital Partners, LLC (Filed With SEC on March 11, 2019)

Form of Pre-funded Warrant (Filed With SEC on March 11, 2019)

Form of Warrant (Filed With SEC on March 11, 2019)

Form of Securities Purchase Agreement among Altimmune, Inc. and certain investors (Filed With SEC on March 11, 2019)

General Release, dated as of November 30, 2018, by and between William J. Enright and Altimmune, Inc (Filed With SEC on December 3, 2018)

Consulting Agreement, dated as of November 30, 2018, by and between William J. Enright and Altimmune, Inc (Filed With SEC on December 3, 2018)

Altimmune, Inc. 2018 Inducement Grant Plan (Filed With SEC on December 3, 2018)

Form of Non-Qualified Stock Option Agreement under the Altimmune, Inc. 2018 Inducement Grant Plan (Filed With SEC on December 3, 2018)

Form of Restricted Stock Agreement under the Altimmune, Inc. 2018 Inducement Grant Plan (Filed With SEC on December 3, 2018)

Form of Restricted Stock Agreement under the Altimmune, Inc. 2017 Omnibus Incentive Plan (Filed With SEC on December 3, 2018)

Employment Agreement, dated as of November 16, 2018, by and between Dr. Vipin K. Garg and Altimmune, Inc (Filed With SEC on November 27, 2018)

Placement Agency Agreement among Altimmune, Inc. and Roth Capital Partners, LLC (Filed With SEC on October 9, 2018)

Form of Pre-funded Warrant (Filed With SEC on October 9, 2018)

Form of Warrant (Filed With SEC on October 9, 2018)

Form of Securities Purchase Agreement among Altimmune, Inc. and certain investors (Filed With SEC on October 9, 2018)

Form of Underwriting Agreement (Filed With SEC on September 26, 2018)

Form of Pre-funded Warrant (Filed With SEC on September 26, 2018)

Form of Warrant (Filed With SEC on September 26, 2018)

Form of Underwriters Warrant (Filed With SEC on September 26, 2018)

Amendment No. 4 to Contract Award issued by the Biomedical Advanced Research and Development Authority of the United States Department of Health and Human Services, dated... (Filed With SEC on September 26, 2018)

Placement Agency Agreement by and between Altimmune, Inc. and Roth Capital Partners, LLC (Filed With SEC on September 25, 2018)

Form of Securities Purchase Agreement among Altimmune, Inc. and certain investors (Filed With SEC on September 25, 2018)

Consulting Agreement, dated May 21, 2018, by and between Altimmune, Inc. and William Brown (Filed With SEC on August 14, 2018)

General Release, dated as of May 29, 2018, by Elizabeth A. Czerepak (Filed With SEC on August 14, 2018)

Form of Exchange Agreement (Filed With SEC on July 16, 2018)

Form of Exchange Note (included as Exhibit A to Exhibit 10.1 hereto) (Filed With SEC on June 25, 2018)

Form of Exchange Note (included as Exhibit A to Exhibit 10.2 hereto) (Filed With SEC on June 25, 2018)

Incentive Stock Option Agreement under the Altimmune, Inc. 2017 Omnibus Incentive Plan, dated as of September 22, 2017, by and between Altimmune, Inc. and William Enright (Filed With SEC on November 9, 2017)

Incentive Stock Option Agreement under the Altimmune, Inc. 2017 Omnibus Incentive Plan, dated as of September 22, 2017, by and between Altimmune, Inc. and Elizabeth Czerepak (Filed With SEC on November 9, 2017)

Incentive Stock Option Agreement under the Altimmune, Inc. 2017 Omnibus Incentive Plan, dated as of September 22, 2017, by and between Altimmune, Inc. and William Enright (Filed With SEC on September 28, 2017)

Incentive Stock Option Agreement under the Altimmune, Inc. 2017 Omnibus Incentive Plan, dated as of September 22, 2017, by and between Altimmune, Inc. and Elizabeth Czerepak (Filed With SEC on September 28, 2017)

15,656 Series B Convertible Preferred Shares Warrants to Purchase 2,345,427 Common Shares ALTIMMUNE, INC. Preferred Stock PLACEMENT AGENCY AGREEMENT (Filed With SEC on August 17, 2017)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on August 17, 2017)

[FORM OF WARRANT] ALTIMMUNE, INC. WARRANT TO PURCHASE COMMON STOCK (Filed With SEC on August 17, 2017)

CONTRACT TABLE OF CONTENTS (Filed With SEC on August 14, 2017)

ITEM NO. (A) (Filed With SEC on August 14, 2017)

AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 14, 2017)

First Amendment to Amended and Restated Exclusive License Agreement (Filed With SEC on August 14, 2017)

Second Restated LicenseAgreement VAXIN CRUCELL (Filed With SEC on August 14, 2017)

AMENDMENT NO. 1 TO SECONDRESTATED LICENSE AGREEMENT (Filed With SEC on August 14, 2017)

FORM OF INDEMNIFICATION AGREEMENT (Filed With SEC on August 14, 2017)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2017)

FirstAmendment to the Amended and Restated Employment Agreement between Altimmune, Inc. and William J. Enright (Filed With SEC on August 14, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2017)

FirstAmendment to the Employment Agreement between Altimmune, Inc. and Elizabeth Czerepak (Filed With SEC on August 14, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2017)

CONVERTIBLE PROMISSORY NOTE PURCHASE AGREEMENT (Filed With SEC on August 14, 2017)

ALTIMMUNE, INC. 2017 OMNIBUS INCENTIVE PLAN (Filed With SEC on May 8, 2017)

INCENTIVE STOCK OPTION AGREEMENT PURSUANT TO THE ALTIMMUNE, INC. 2017 OMNIBUS INCENTIVEPLAN * * * * * (Filed With SEC on May 8, 2017)

NONQUALIFIED STOCK OPTION AGREEMENT PURSUANT TO THE ALTIMMUNE, INC. 2017 OMNIBUS INCENTIVEPLAN * * * * * (Filed With SEC on May 8, 2017)

(Signature Page Follows) (Filed With SEC on March 29, 2017)

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION by and among PHARMATHENE, INC., MUSTANG MERGER SUB CORP I INC., MUSTANG MERGER SUB II LLC ALTIMMUNE, INC., and SHAREHOLDER... (Filed With SEC on January 19, 2017)

FORM OF Parent VOTING AGREEMENT (Filed With SEC on January 19, 2017)

FORM OF PHARMATHENE LOCK-UP AGREEMENT (Filed With SEC on January 19, 2017)

FORMOF COMPANY LOCK-UP AGREEMENT (Filed With SEC on January 19, 2017)

EMPLOYMENT AGREEMENT (Filed With SEC on March 11, 2016)

SECTION 382 RIGHTS AGREEMENT (Filed With SEC on November 25, 2015)

SEPARATION AGREEMENT AND GENERAL RELEASE AND WAIVER (Filed With SEC on May 7, 2015)

CONTRACT TABLE OF CONTENTS (Filed With SEC on November 6, 2014)

TERMINATION AGREEMENT (Filed With SEC on December 2, 2013)

Formof Amendment to Employment Agreement (Filed With SEC on November 7, 2013)

AGREEMENT AND PLAN OF MERGER among PHARMATHENE, INC., TAURUS MERGER SUB, INC., THERACLONE SCIENCES, INC., and StevenGillis, Ph.D., AS SECURITYHOLDERS’ REPRESENTATIVE Dated as of... (Filed With SEC on August 1, 2013)

PHARMATHENE,INC. VOTING AND LOCK-UP AGREEMENT (Filed With SEC on August 1, 2013)

THERACLONEVOTING AND LOCK-UP AGREEMENT (Filed With SEC on August 1, 2013)

FOrmof Board Composition AGREEMENT (Filed With SEC on August 1, 2013)

FORMOF Post-Closing Lock-Up Agreement (Filed With SEC on August 1, 2013)

EMPLOYMENT AGREEMENT (Filed With SEC on May 8, 2013)

PHARMATHENE, INC. Up to $15,000,000 of Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement (Filed With SEC on March 25, 2013)

LOAN AND SECURITY AGREEMENT (Filed With SEC on April 3, 2012)

FORM OF WARRANT (Filed With SEC on April 3, 2012)

EMPLOYMENT AGREEMENT (Filed With SEC on March 8, 2012)

OFFER TO PURCHASE (Filed With SEC on March 8, 2012)

PHARMATHENE, INC. PLACEMENT AGENCY AGREEMENT (Filed With SEC on June 10, 2011)

Form of Unit Subscription Agreement SUBSCRIPTION AGREEMENT (Filed With SEC on June 10, 2011)

PHARMATHENE, INC. WARRANT TO PURCHASE COMMON STOCK To Purchase _________ Shares of Common Stock (Filed With SEC on June 10, 2011)

FORM OF RESTRICTED STOCK AGREEMENT (Filed With SEC on May 11, 2011)

PHARMATHENE, INC. 2007 LONG-TERM INCENTIVE PLAN FORM OF GRANT OF NONQUALIFIED STOCK OPTION (Filed With SEC on May 11, 2011)

EMPLOYMENT AGREEMENT (Filed With SEC on March 31, 2011)

EMPLOYMENTAGREEMENT (Filed With SEC on December 30, 2010)

PHARMATHENE,INC. 4,300,000Shares of Common Stock UnderwritingAgreement (Filed With SEC on November 1, 2010)

[FORM]EARLYCONVERSION AGREEMENT (Filed With SEC on November 1, 2010)

ADDENDUMA INDEMNIFICATIONPROVISIONS (Filed With SEC on July 20, 2010)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on July 20, 2010)

COMMONSTOCK PURCHASE WARRANT PHARMATHENE,INC. (Filed With SEC on July 20, 2010)

Amendmentto Employment Agreement (Filed With SEC on May 24, 2010)

Exhibit 10.32 PharmAthene, Inc. Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Confidential Portionsdenoted by [***] (Filed With SEC on May 13, 2010)

ADDENDUMA INDEMNIFICATIONPROVISIONS (Filed With SEC on April 8, 2010)

SECURITIESPURCHASE AGREEMENT (Filed With SEC on April 8, 2010)

COMMONSTOCK PURCHASE WARRANT PHARMATHENE,INC. (Filed With SEC on April 8, 2010)

EMPLOYMENTAGREEMENT (Filed With SEC on March 26, 2010)

PharmAthene, Inc. Confidential Materials Omittedand Filed Separately with the Securities and ExchangeCommission Confidential Portions denoted by[***] (Filed With SEC on August 13, 2009)

SENIORUNSECURED CONVERTIBLE NOTE (Filed With SEC on August 3, 2009)

PHARMATHENE, INC. WARRANT TO PURCHASE SHARES OF COMMON STOCK, PAR VALUE $0.0001PER SHARE (Filed With SEC on August 3, 2009)

NOTE AND WARRANT PURCHASE AGREEMENT (Filed With SEC on August 3, 2009)

REGISTRATION RIGHTS AGREEMENT (Filed With SEC on August 3, 2009)

FORM OF AMENDMENT TO EMPLOYMENT AGREEMENT (Filed With SEC on May 15, 2009)

CONSENT, ASSUMPTION AND SECOND LOANMODIFICATION AGREEMENT (Filed With SEC on May 15, 2009)

PharmAthene, Inc. Confidential Materials Omitted andFiled Separately with the Securities and Exchange Commission Confidential Portions denoted by[***] PRIVATE BETWEEN THE PARTIES... (Filed With SEC on May 15, 2009)

PharmAthene, Inc. Confidential Materials Omitted and Filed Separatelywith the Securities and Exchange Commission Confidential Portions denoted by [***] PRIVATE BETWEEN THE PARTIES... (Filed With SEC on May 15, 2009)

1251 Avenue of the Americas, 20thFloor, New York, NY10020 Tel: 212 ###-###-#### Fax ###-###-#### www.rodm.com Member: FINRA, SIPC (Filed With SEC on March 27, 2009)

SECURITIES PURCHASE AGREEMENT (Filed With SEC on March 27, 2009)

COMMON STOCK PURCHASE WARRANT PHARMATHENE, INC. (Filed With SEC on March 27, 2009)

INDEMNIFICATIONAGREEMENT (Filed With SEC on January 27, 2009)

FORM OF EMPLOYMENTAGREEMENT (Filed With SEC on August 14, 2008)

Form of Confidentiality and Non-SolicitationAgreement (Filed With SEC on August 14, 2008)

PharmAthene, Inc. Confidential Materials Omitted and FiledSeparately with the Securities and Exchange Commission Confidential Portions denoted by [***] (Filed With SEC on August 14, 2008)

DATED APRIL 2, 2008 TRANSITIONALSERVICES AGREEMENT between AVECIABIOLOGICS LIMITED and PHARMATHENEUK LIMITED (Filed With SEC on June 18, 2008)

DATED 2nd APRIL 2008 AMENDMENTAGREEMENT among (Filed With SEC on April 8, 2008)

HEALTHCARE ACQUISITION CORP. 2007 LONG-TERM INCENTIVE COMPENSATION PLAN ARTICLE I PURPOSE (Filed With SEC on August 9, 2007)

EMPLOYMENT AGREEMENT (Filed With SEC on August 9, 2007)

AMENDMENT TO UNIT PURCHASE OPTION (Filed With SEC on January 25, 2007)

WARRANT CLARIFICATION AGREEMENT (Filed With SEC on January 25, 2007)

Members NASD & SIPC 405 Lexington Ave. * New York, NY 10174 * tel ###-###-#### * (800) 724-0761 * fax ###-###-#### * www.maximgrp.com New York, NY * Woodbury, NY * Chicago, IL*... (Filed With SEC on January 25, 2007)

AGREEMENT AND PLAN OF MERGER DATED AS OF JANUARY 19, 2007 BY AND AMONG HEALTHCARE ACQUISITION CORP., PAI ACQUISITION CORP. AND PHARMATHENE, INC. TABLE OF CONTENTS (Filed With SEC on January 22, 2007)

NOTE EXCHANGE AGREEMENT (Filed With SEC on January 22, 2007)

[FORM OF SENIOR UNSECURED CONVERTIBLE NOTE] (Filed With SEC on January 22, 2007)

FORM OF REGISTRATION RIGHTS AGREEMENT (Filed With SEC on January 22, 2007)

Form of Lock-Up Agreement (Filed With SEC on January 22, 2007)

- 2- - (Filed With SEC on June 10, 2005)

Category

Industry

Companies

Contracts

Altimmune, Inc. Contracts & Agreements